EPS Beat for Biogen; Outlook Weak - Analyst Blog

By
A A A

Biogen Idec ( BIIB ) reported fourth-quarter earnings per share of $1.51, well above the Zacks Consensus Estimate of $1.46 and the year-ago earnings of $1.41. Fourth quarter results were boosted by higher revenues which came in at $1.3 billion, up 9%. Revenues were in-line with the Zacks Consensus Estimate.

Full-year earnings came in at $5.85 per share, 3 cents above the Zacks Consensus Estimate and well above the year-ago earnings of $5.03 per share. Excluding the impact of stock-based compensation expense, full year 2011 earnings came in at $5.90 per share, up 14.6%.

Full-year revenues increased 5% to $5 billion, in-line with the Zacks Consensus Estimate.

The Quarter in Detail

Fourth quarter performance was driven by Biogen's multiple sclerosis ( MS ) franchise. Fourth quarter Tysabri revenues came in at $269 million, up 11.5% from the prior-year period. Global in-market net sales of Tysabri, which is partnered with Elan Corp. ( ELN ), came in at $380 million (up 14%) in the fourth quarter of 2011. Tysabri global sales consisted of US sales of $196 million and ROW (Rest of the World) sales of $183 million.

Biogen estimates that as of the end of December 2011, about 64,400 patients were on commercial and clinical Tysabri therapy worldwide. This represents an increase from the 63,500 patients reported by the company in the third quarter of 2011.

We note that there was a slowdown in new patient additions on a sequential basis. This could be due to the penetration of  the anti-JC virus antibody assay.

Tysabri's label was updated so as to include anti-JC virus antibody status as one potential factor that could help stratify the risk of progressive multifocal leukoencephalopathy ( PML ) occurring in patients treated with Tysabri. The inclusion of the anti-JCV virus antibody status in the product label should help drive patient growth.

Meanwhile, Biogen's lead MS product Avonex posted fourth quarter sales of $703 million (up 7.5%). Biogen has been working on driving Avonex sales. Avonex Pen gained approval in the EU for use in patients with relapsing multiple sclerosis and patients with a single demyelinating event. The availability of Avonex Pen should help improve convenient administration. The rollout of Avonex Pen should increase patient and physician interest in Avonex.

We note that both Avonex and Tysabri are facing additional competition in the form of Novartis' ( NVS ) Gilenya which was launched in early Oct 2010. Results from a study comparing Gilenya with Avonex showed that Gilenya reduced relapse rates by 52% at one year compared with Avonex. Being an oral therapy, Gilenya could find quick acceptance as currently available therapies require injection or infusion.

However, Biogen is looking to bring BG-12, its oral MS candidate, to market. The company reported impressive data on the candidate and expects to file for approval in the first half of 2012. BG-12 could become a leader in the oral MS market once launched.

Rituxan revenues remained flat at $258 million in the fourth quarter. Biogen and partner Roche ( RHHBY ) have been working on driving Rituxan growth by expanding the label for additional indications.

In January 2011, Rituxan gained FDA approval for the maintenance treatment of patients with advanced follicular lymphoma who responded to initial treatment with Rituxan and chemotherapy. Rituxan also gained approval as a combination treatment (with corticosteroids) for adults with Wegener's granulomatosis and microscopic polyangiitis.

Revenues from other products increased 71.4% to $24 million. Royalties increased 16% to $53 million.

2012 Outlook Disappoints

Biogen provided its outlook for 2012. The company earnings of $6.10 - $6.20 per share on low to mid-single digit revenue growth. The company's outlook for 2012 was disappointing - the Zacks Consensus Estimate already stands well above the company's guidance range at $6.27 per share.

Biogen's guidance for expenses was higher than expected. While the company expects to spend 24% to 25% of total revenue on R&D, SG&A spend is expected to be about 22% to 23% of total revenue.

We currently have a Neutral recommendation on Biogen, which carries a Zacks #3 Rank (short-term Hold rating).


 
BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report
 
ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report
 
NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BIIB , ELN , MS , NVS , PML

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

64,159,633
  • $100.86 ▼ 0.76%
63,552,623
  • $16.71 ▼ 0.18%
60,140,251
  • $42.71 ▲ 0.38%
52,385,870
  • $17.51 ▲ 5.86%
50,329,585
  • $13.75 ▲ 29.84%
43,337,551
  • $16.16 ▼ 1.40%
40,126,911
  • $3.605 ▲ 0.56%
39,836,742
  • $3.81 ▼ 2.56%
As of 9/16/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com